Derbala Moutaz, Amer Aliaa
Department of Gastroenterology & Hepatology, Hamad Medical Corporation, Doha, P.O. Box #3050, Qatar.
Cases J. 2009 Sep 15;2:7927. doi: 10.1186/1757-1626-0002-0000007927.
Genotype 4 Hepatitis C virus represents approximately 20% of global Hepatitis C virus infection and is the source of a considerable burden to health-care providers across the globe. Many studies reported that interferon reduces the risk of hepatocellular carcinoma in patients with chronic hepatitis C.Hereby, we are reporting two cases of hepatocellular carcinoma in Hepatitis C virus-genotype 4 after complete viral eradication and in absence of cirrhosis. We aim to highlight the possible direct oncogenic effect of Hepatitis C virus-genotype 4, particularly with concomitant bilharzial infection and the importance of life-log follow up of these patients even in absence of cirrhosis.
4型丙型肝炎病毒约占全球丙型肝炎病毒感染的20%，给全球医疗服务提供者带来了相当大的负担。许多研究报告称，干扰素可降低慢性丙型肝炎患者患肝细胞癌的风险。在此，我们报告两例4型丙型肝炎病毒感染患者在病毒完全清除且无肝硬化的情况下发生肝细胞癌的病例。我们旨在强调4型丙型肝炎病毒可能的直接致癌作用，尤其是在合并血吸虫感染的情况下，以及即使在无肝硬化的情况下对这些患者进行长期随访的重要性。
